Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 2, 2000, Pages 793-801

  Stormer, E ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; MIRTAZAPINE;

ACCURACY; ARTICLE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME KINETICS; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; LIVER; LIVER MICROSOME; METABOLITE; PRIORITY JOURNAL; TISSUE LEVEL;

BIOTRANSFORMATION; COMPARATIVE STUDY; CYTOCHROME P-450 ENZYME SYSTEM; DATA INTERPRETATION, STATISTICAL; DNA, COMPLEMENTARY; HUMAN; ISOENZYMES; KINETICS; MIANSERIN; MICROSOMES, LIVER; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033771687     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Distribution of mirtazapine (Remeron) in thirteen postmortem cases
2. Allelic and functional variability of cytochrome P450 2C9
3. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
4. Xenobiotic metabolising human cells as tools for pharmacological and toxicological research
5. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
6. In vitro and in vivo studies on the disposition of mirtazapine in humans
7. Pharmacokinetics and biotransformation of mirtazapine in human volunteers
8. Safety in overdose of mirtazapine: A case report
9. Human cytochromes mediating sertraline biotransformation: Seeking attribution
10. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
11. Suicide attempts with mirtazapine overdose without complications
12. 5 in reconstituted menooxygenase systems containing various forms of hepatic microsomal cytochrome P-450
13. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
14. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes
15. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
16. Tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
17. Tissue distribution of mirtazapine (Remeron) in postmortem cases
18. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs
19. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
20. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
21. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8
22. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
23. Non-fatal mirtazapine overdose
24. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
25. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
26. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
27. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
28. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6 and 3A4
29. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
30. Citalopram and desmethylcitalopram in vitro: Human cytochromas mediating transformation, and cytochrome inhibitory effects
31. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
32. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with keteconazole
33. Alprazolam metabolism in vitro: Studies of human, monkey, mouse and rat liver microsomes
34. 5 and NADPH-cytochrome P-450 reductase in an entire human liver